How many institutions held MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share in Q4 2025?

73 institutional investors reported MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share for Q4 2025. Use the holders table for investor-level position and value details.

Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR)

Q: What does CUSIP 61023L207 represent in this 13F holders report?

CUSIP 61023L207 is the security identifier for MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

CUSIP: 61023L207

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 6,743,758
Total 13F shares: 5,525,394
Share change: +1,189,049
Total reported value: $360,692,606
Price per share: $65.30
Number of holders: 73
Value change: +$75,159,494
Number of buys: 55
Number of sells: 14

Quarterly Holders Quick Answers

What is CUSIP 61023L207?
CUSIP 61023L207 identifies MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 61023L207:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024

Top shareholders of MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
JANUS HENDERSON GROUP PLC	13F 13D/G	Company	20% from 13D/G	1,287,368	$105,313,139	—	30 Sep 2025	13F 13D/G
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	9.8%	659,195	$53,836,456	—	30 Sep 2025	13F
Hendricks Diane	3/4/5	10%+ Owner	8.4%	567,580	$50,213,802	—	16 Dec 2025	3/4/5
RA CAPITAL MANAGEMENT, L.P.	13D/G 13F	Company	9.9%	667,632	$43,402,756	-$4,890,637	31 Dec 2025	13D/G 13F
ASTRAZENECA PLC	13D/G	—	7.8%	522,667	$34,126,392	$0	31 Dec 2025	13D/G
Adage Capital Management, L.P.	13D/G	—	9.9%	599,195	$26,706,121	$0	31 Dec 2024	13D/G
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	3.4%	231,463	$18,903,584	—	30 Sep 2025	13F
Tactic Pharma LLC	3/4/5	10%+ Owner	4%	272,026	$17,303,519	-$34,999,957	24 Sep 2025	3/4/5
VANGUARD GROUP INC	13F	Company	3.1%	208,218	$17,005,165	—	30 Sep 2025	13F
BlackRock, Inc.	13F	Company	3%	203,751	$16,640,345	—	30 Sep 2025	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	2.4%	159,765	$13,048,008	—	30 Sep 2025	13F
Saturn V Capital Management LP	13F	Company	2.3%	155,370	$12,689,068	—	30 Sep 2025	13F
TCG Crossover Management, LLC	13F	Company	2.3%	153,000	$12,495,510	—	30 Sep 2025	13F
ADAR1 Capital Management, LLC	13F	Company	1.9%	129,999	$10,617,018	—	30 Sep 2025	13F
Vivo Capital, LLC	13F	Company	1.3%	90,500	$7,391,135	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.3%	84,961	$6,940,459	—	30 Sep 2025	13F
Affinity Asset Advisors, LLC	13F	Company	1.2%	79,483	$6,491,377	—	30 Sep 2025	13F
STATE STREET CORP	13F	Company	1.1%	72,238	$5,899,677	—	30 Sep 2025	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	0.96%	64,636	$5,278,822	—	30 Sep 2025	13F
Ally Bridge Group (NY) LLC	13F	Company	0.96%	64,455	$5,264,040	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.4%	26,855	$2,193,247	—	30 Sep 2025	13F
Bank of New York Mellon Corp	13F	Company	0.25%	17,170	$1,402,260	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	0.23%	15,711	$1,283,118	—	30 Sep 2025	13F
BARCLAYS PLC	13F	Company	0.22%	15,082	$1,231,747	—	30 Sep 2025	13F
Informed Momentum Co LLC	13F	Company	0.22%	14,629	$1,194,750	—	30 Sep 2025	13F
Alyeska Investment Group, L.P.	13F	Company	0.18%	12,215	$997,599	—	30 Sep 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.17%	11,797	$963,461	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0.12%	7,973	$651,154	—	30 Sep 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.11%	7,334	$598,968	—	30 Sep 2025	13F
Arthur J. Klausner	3/4/5	Director	— mixed-class rows	11,686 mixed-class rows	$596,604	-$343,889	18 Dec 2025	3/4/5
Christopher M. Starr	3/4/5	Director	— mixed-class rows	17,977 mixed-class rows	$538,894	-$672,020	02 Dec 2025	3/4/5
GOLDMAN SACHS GROUP INC	13F	Company	0.1%	6,525	$532,897	—	30 Sep 2025	13F
Kim R. Tsuchimoto	3/4/5	Director	— mixed-class rows	14,410 mixed-class rows	$459,453	-$356,171	02 Dec 2025	3/4/5
GERBER, LLC	13F	Company	0.08%	5,601	$457,434	—	30 Sep 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.08%	5,288	$431,863	—	30 Sep 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.06%	4,328	$353,468	—	30 Sep 2025	13F
Nuveen, LLC	13F	Company	0.06%	4,221	$344,729	—	30 Sep 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.06%	4,012	$327,660	—	30 Sep 2025	13F
Lavina Talukdar	3/4/5	Director	— mixed-class rows	16,925 mixed-class rows	$308,022	—	02 Dec 2025	3/4/5
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	13F	Company	0.05%	3,508	$286,498	—	30 Sep 2025	13F
MetLife Investment Management, LLC	13F	Company	0.04%	2,538	$207,278	—	30 Sep 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.03%	2,321	$189,556	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.03%	2,124	$173,467	—	30 Sep 2025	13F
AlphaQuest LLC	13F	Company	0.03%	1,935	$158,031	—	30 Sep 2025	13F
Michael J. Brown	3/4/5	Director	— class O/S missing	402,530	$136,941	—	31 Dec 2023	3/4/5
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	13F	Company	0.02%	1,629	$133,040	—	30 Sep 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.02%	1,491	$121,770	—	30 Sep 2025	13F
Quan Anh Vu	3/4/5	Chief Financial Officer	— mixed-class rows	18,461 mixed-class rows	$104,925	+$104,925	26 Dec 2025	3/4/5
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.02%	1,200	$98,004	—	30 Sep 2025	13F
Andrew Paul Mazar	3/4/5	Chief Scientific Officer, Director	— mixed-class rows	277,584 mixed-class rows	$94,434	—	31 Mar 2022	3/4/5

Institutional Holders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) as of Q4 2025

As of 31 Dec 2025, Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) was held by 73 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,525,394 shares. The largest 10 holders included JANUS HENDERSON GROUP PLC, RA CAPITAL MANAGEMENT, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., Saturn V Capital Management LP, VANGUARD GROUP INC, BlackRock, Inc., ADAR1 Capital Management, LLC, WELLINGTON MANAGEMENT GROUP LLP, Siren, L.L.C., and DEERFIELD MANAGEMENT COMPANY, L.P.. This page lists 73 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.